RT Journal Article
SR Electronic
T1 Sensory profiling in classical Ehlers-Danlos syndrome: a case-control study revealing pain characteristics, somatosensory changes, and impaired pain modulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23286404
DO 10.1101/2023.02.24.23286404
A1 Colman, Marlies
A1 Syx, Delfien
A1 de Wandele, Inge
A1 Rombaut, Lies
A1 Wille, Deborah
A1 Malfait, Zoë
A1 Meeus, Mira
A1 Malfait, Anne-Marie
A1 Van Oosterwijck, Jessica
A1 Malfait, Fransiska
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.24.23286404.abstract
AB Pain is one of the most important, yet poorly understood complaints in heritable connective tissue disorders (HCTD) caused by monogenic defects in extracellular matrix molecules. This is particularly the case for Ehlers-Danlos syndromes (EDS), paradigm collagen-related disorders. This study aimed to identify the pain signature and somatosensory characteristics in the rare classical type of EDS (cEDS) caused by defects in type V or rarely type I collagen. We used static and dynamic quantitative sensory testing and validated questionnaires in 19 individuals with cEDS and 19 matched controls.Individuals with cEDS reported clinically relevant pain/discomfort (VAS ≥5/10 in 32% for average pain intensity the past month) and worse health -related quality of life. Altered sensory profile was found in the cEDS group with higher (p=0.04) detection thresholds for vibration stimuli at the lower limb indicating hypoesthesia, reduced thermal sensitivity with more (p<0.001) paradoxical thermal sensations, and hyperalgesia with lower pain thresholds to mechanical (p<0.001) stimuli at both the upper and lower limbs and to cold (p=0.005) stimulation at the lower limb. Using a parallel conditioned pain paradigm, the cEDS group showed significantly smaller antinociceptive responses (p-value between 0.005 and 0.046) suggestive of impaired endogenous central pain modulation.In conclusion, Individuals with cEDS report chronic pain and worse health-related quality of life, and present altered somatosensory perception. This study is the first to systematically investigate pain and somatosensory characteristics in a genetically defined HCTD and provides interesting insights on the possible role of the ECM in the development and persistence of pain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMC is a PhD research fellow funded by the Research Foundation − Flanders (FWO) [11B7921N]. DS is a postdoctoral fellow funded by the FWO [12Q5920N]. FM is a senior clinical investigator funded by the FWO [1842318N]. This work was supported by the FWO ([3G041519] to FM), Ghent University ([GOA019-21] to FM), Association francaise des syndromes dEhlers-Danlos (AFSED), The Ehlers-Danlos Society, Zebrapad vzw, and National Institute of Health, NIAMS, [P30AR079206] to AMM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complied with the Declaration of Helsinki and was approved by the Ethical Committee of Ghent University Hospital (B670201941418). All participants were fully informed about the experimental procedures, and all provided written informed consent before inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and program codes used in the analysis will not be made available to any researcher after publication. Subjects indicated that they had no objection of the use of anonymized data for this research, but they did not provide permission to use the data for other research.